The tweet was deleted by the author.
But we saved everything 🙂.
Pfizer announced that new Phase 2b data from its obesity pipeline will be presented at a late-breaking expert symposium during the #ADASciSessions this weekend.
Pfizer stated that it is working to advance treatment approaches intended to address the many needs of people living with obesity and related comorbidities. Additional information is available at the link provided by the company.
View post on X Loading...
Pfizer ($25.70) is currently trading below the MA-20 ($25.85), MA-50 ($26.64), and MA-200 ($25.84) on the D1 timeframe, reflecting clear short-term, medium-term, and long-term bearish pressure from sellers. The Ichimoku Kijun level at $26.39 is above the current price, acting as immediate resistance. Near-term support is clustered around the MA-200 ($25.84), with key support at MA-100 ($26.65). Near-term resistance is marked by the MA-20 ($25.85), while the Ichimoku Kijun ($26.39) serves as key resistance.
Trend momentum remains negative on D1 as MACD signals a strong sell and ADX sits at weak levels, suggesting a lack of strong directional movement. Oversold signals are highlighted by RSI (37.35), CCI (-128.75), Stoch RSI (24.49), and BBP (-0.29), which all indicate seller dominance and potential for a technical bounce. AO on D1 supports the prevailing bearish tone, while weekly price action shows Pfizer has fallen $0.51 (1.91%) from the previous close of $26.21, with current price positioned in the middle of the weekly range. Weekly volatility stands at 3.76%. This points to a steady decline from recent highs, in line with momentum signals, though daily oscillators are approaching oversold territory. In today's session, the price has rebounded 1.32%, reflecting a short-term attempt at recovery.
For the upcoming week, the expected range is $24.90–$25.90, keeping price action between the 52-week low ($23.11) and high ($28.74), and reflecting realistic movement given recent volatility. The probability of a price increase is very low (less than 20%), with a further decline being more likely, as only ADX on W1 gives a "Buy" signal against three "Sell/Neutral" readings from RSI, MACD, and MA-50 on W1. The baseline scenario sees Pfizer consolidating between $24.90 and $25.90. A bullish scenario would require a break above near-term resistance at $25.85 and Kijun at $26.39, potentially opening room for further gains, but this remains less likely based on the current setup. The bearish scenario would see a break below $25.84, risking a move toward $24.90 or slightly lower if selling intensifies, with significant technical oversold conditions offering the prospect for at least short-term stabilization.
Earlier, analysts noted that Pfizer shares were experiencing persistent selling pressure but maintained underlying long-term support. In light of current market developments, investors should closely monitor any shifts in momentum, as a clear break from established support could redefine risk and trading direction for PFE.